Kornimate/medical-research-clean huggingface dataset:
tomosynthesis mammographic imaging screening trial

Conditions: Breast Cancer

Summary: a randomized screening trial to compare the diagnostic accuracy of screening for breast cancer with three-dimensional digital breast tomosynthesis (dbt) plus two-dimensional full-field digital mammography (ffdm) versus ffdm alone.

the tomosynthesis mammography imaging screening trial (tmist) lead-in is being conducted to ensure that all eastern cooperative oncology group / american college of radiology imaging network (ecog/acrin) tmist components are properly functional and to provide an opportunity for fine tuning before launching the full tmist. the accrual target for tmist lead-in is 6354 participants (one tenth of the projected enrollment target for tmist) at three lead-in study sites: 1. sunnybrook health sciences centre in toronto, 2. vancouver (under the auspices of the screening mammography programme of british columbia) and 3. the ottawa hospital.

Eligibility criteria:
inclusion criteria: * asymptomatic women age 40 and over * scheduled for screening mammogram * able to tolerate digital breast tomosynthesis and full-field digital mammographic imaging required by protocol * willing and able to provide a written informed consent. exclusion criteria: * presenting for mammography with symptoms of breast disease * have new breast complaints (e.g. lump, nipple discharge) * have had a mammogram of both breasts within the last 11 months * previous personal history of breast cancer * has breast enhancements (e.g. implants or injections) * pregnancy or intent to become pregnant.

Keywords: tomosynthesis digital breast tomosynthesis (dbt) breast imaging full-field digital mammography breast screening
the swallowing function of oral cancer surgery

Conditions: The Swallowing Changes

Summary: this study enrolled patients who underwent oral cancer resection. swallowing function, muscle status, and nutritional status were assessed before treatment, one month after treatment, and between three months to one year post-treatment.

dysphagia is a common and debilitating symptom among patients who undergo oral cancer resection with reconstruction followed by adjuvant radiotherapy. during the course of the disease, approximately 20% to 98% of patients experience swallowing difficulties. this is primarily caused by tumor destruction, postoperative sequelae from surgical resection, and the adverse effects of radiotherapy and chemotherapy. the use of chemotherapy or radiotherapy-particularly when combined-increases the incidence of complications such as oropharyngeal mucositis, odynophagia, dysgeusia, xerostomia, nausea, vomiting, and fatigue. these complications may lead to dehydration and significant weight loss, which in turn negatively impact nutritional status, functional ability, and quality of life. this study enrolled patients who underwent oral cancer surgery. swallowing function, muscle status, and nutritional status were assessed before treatment, one month after treatment, and between three months to one year post-treatment.

Eligibility criteria:
inclusion criteria: * patients undergoing oral cancer exclusion criteria: * patients unable to unable to cooperate with the examination

Keywords: oral cancer surgery swallowing nutrition
drug eluting balloon for treatment of unstable angina

Conditions: Angina, Unstable

Summary: this study was to investigate the effect and safety of drug eluting balloon combined for treatment of unstable angina.

patients with unstable angina were randomized to drug eluting stent only or drug eluting balloon group. angiographic follow-up was performed after 12 months. the primary endpoints were late lumen loss (lll) and the secondary endpoints were target lesion revascularization (tlr),and the major adverse cardiovascular events (mace) .

Eligibility criteria:
inclusion criteria: * patients \> 18, \< 80 years old, with unstable angina * single-vessel or double-vessel disease * length of target lesion \< 25mm * diameter of target vessel \>2.5mm, \< 3.5mm exclusion criteria: * left main disease * chronic total occlusion * severe tortuosity * heavy calcification * severe liver failure, moderate or severe kidney failure * malignant disease * active infectious disease * pregnancy or breastfeeding
in-utero death and birth mortality in reunion island

Conditions: Pregnancy Loss; Infant Death

Summary: infant mortality is still relevant despite the improvement and the accessibility of hospital care. premature birth are two fold higher than in metropolitan france. some factors has been suspected such as precariousness, alcoholism, congenital malformation, care accessibility, epidemic environment ... nevertheless, the impact of these factors on foetal death or new-born death are not yet sufficiently quantified to provide appropriate care and prevention action in reunion island.

through the analysis of interview of the mothers that have lost their infant during pregnancy or just after birth, the study aims to draw a picture of the pregnancy cares offer and pregnancy conditions in reunion island. this study is an non interventional case-control study. socio-economic conditions, pregnancy care and prevention are screened to identified the major cause of foetal or new-born death in reunion island. these data are still lacking and will be useful to identify which public health actions that should be organized.

Eligibility criteria:
inclusion criteria: * case: foetal death (foetus weighing more than 500 g or more than 22-amenorrhea weeks old) or new-born death (premature: more than 23-amenorrhea weeks old or mature) * control: premature (more than 23-amenorrhea weeks old) or mature new-born, alive when the leave the hospital exclusion criteria: * medical abortion * second pregnancy during the study period * case under forensic expertise
aspirin effects on emotional reactions

Conditions: Healthy Adults

Summary: the aim of this study is to determine whether the drug aspirin has effects on emotional reactivity, emotional memory, and risk-taking behaviors.

the goal of this study is to determine if aspirin (acetylsalicylic acid) alters emotional reactions to emotion evoking pictures as well as memory for them. using a double-blind parallel arm study, participants will receive either placebo or a pain-relieving dose of aspirin (500mg). one hour later they will complete 30 minutes of tasks. this will include ratings of emotional pictures and memory for them. the paradigm is similar to previous experiments done in this lab using other cyclooxygenase inhibitors: ibuprofen and acetaminophen (durso, luttrell, \& way, 2015; psychological science, https://doi.org/10.1177/0956797615570366). risk taking on the balloon analogue risk task will also be assessed. participants will be healthy young adult males at ohio state university.

Eligibility criteria:
inclusion criteria: at least 18 years old and biologically male exclusion criteria: due to the use of aspirin in this study, women will be excluded from the study due to potential negative effects it may have on pregnancy participants will also be excluded for the following medical reasons: 1. having an allergy to aspirin, other salicylates, or any other pain reliever/fever reducer. 2. having or recovering from a viral infection such as the chicken pox or flu. 3. having taken aspirin or another nsaid drug (aspirin, ibuprofen, naproxen, or others) within the last 8 hours or plan to take aspirin or another nsaid drug in the 8 hours after the end of the study. 4. having more than three drinks of alcohol in the 8 hours after completion of the study. 5. having asthma, hay fever, nasal polyps, or chronic respiratory disease. 6. impaired liver/kidney or impaired cardiovascular circulation (renal vascular disease, congestive heart failure, volume depletion, major surgery, sepsis or major hemorrhagic events) 7. active or severe liver or kidney disease. 8. an ulcer, history of ulcers or are prone to bleeding. 9. a history of blood clotting defects. 10. severe anemia. 11. taking any of the following drugs: a blood thinning anticoagulant (e.g. warfarin), digoxin, an angiotensin converting enzyme (ace) inhibitor, methotrexate, an oral glucocorticoid (e.g. hydrocortisone),valproic acid, a selective serotonin reuptake inhibitor (ssri; e.g. prozac; zoloft) 12. have had stomach ulcers or bleeding problems. 13. have stomach problems such as heartburn, upset stomach, or stomach pain that does not go away or reoccurs. 14. surgery in the last week or will have a surgery in the next week. 15. high blood pressure. 16. diabetes, gout, or arthritis. 17. low uric acid or glucose-6-phosphate dehydrogenase (g6pd) deficiency.

Keywords: aspirin acetylsalicylic acid emotional reactivity memory risk-taking inflammation
evaluation of antiplatelet effects of different dosages of aspirin in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: the efficacy of low dose aspirin appears to be substantially lower in diabetic patients, compared to patients without diabetes. the aim of the investigators study is to test the laboratory response to different dosing of aspirin in type 2 diabetes mellitus. the investigators will compare the regular dose of 75mg once daily to 75 mg twice daily or to 320 mg once daily. the hypothesis of the study is that twice daily dosing of aspirin may improve the response to aspirin.


Eligibility criteria:
inclusion criteria: * type 2 dm with micro- or macroangiopathy. * hba1c 6-9 % (mono-s method). * need for, or already on-going aspirin treatment. * age 50-75 years * antecubital forearm veins allowing technically good sampling for platelet studies exclusion criteria: * diet controlled dm. * acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable angina pectoris), or revascularization by pci or by-pass surgery within the last 6 months. * acute or chronic kidney disease (p-cystatin c within the reference interval) * acute or chronic liver disease (alat ≤2 times the upper reference value). * a history of gastric or duodenal ulcer disease. * need for treatment with anticoagulants, clopidogrel, nsaid's, or thiazolidinediones. * thrombocytopenia (platelet count \<150 x 109/l) * anticipated need for alteration of concomitant drug therapy during the course of the study. * enrollment in another clinical study. * contraindication(s) to aspirin treatment.

Keywords: niddm aspirin platelet inhibition aspirin treatment
the effect of vtc-g15 (a pentapeptide cleavage product og glp-1) on whole body glucose metabolism in man

Conditions: Insulin Resistance

Summary: to asses the modulating properties of the cleaved pentapeptide product of glp-1 amide.

the investigators have previously demonstrated that infusion of the pentapeptide during hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to maintain stable hyperglycemia without any significant differences in insulin or glucagon secretion. the present study's aim is to examine whether this also occurs in humans. it may be necessary to examine a dose response curve. specifically, in twenty healthy volunteers glucose infusion rate during the peptide infusion will be compared to the glucose infusion rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over design(mg/kg/min).

Eligibility criteria:
inclusion criteria: * bmi 18.5-25; * 33-38 exclusion criteria: * t2d * t1d * hypoglycemic agents
the effect of high-thoracic erector spinae plane block on postoperative pain and diaphragmatic function in posterior cervical spine surgery

Conditions: Cervical Spine Surgery; Pain Management

Summary: posterior cervical spine surgery, often performed on older individuals with significant comorbidities, is one of the most painful surgical operations. anesthesiologists face a unique challenge in managing pain following these surgeries,erector spinae plane block (espb) is a relatively novel block and was first described for chronic thoracic neuropathic pain in 2016.cervical erector spinae plane (esp) block has been described to anesthetize the brachial plexus (bp), however, the mechanism of its clinical effect remains unknown. as the prevertebral fascia encloses the phrenic nerves, bp and erector spinae muscles to form a prevertebral compartment, a local anesthetic injected in the cervical esp could potentially spread throughout the prevertebral compartment


Eligibility criteria:
inclusion criteria: * (asa )classes i and ii * patients of either sex * above the age of 18 who will undergo posterior cervical surgery exclusion criteria: * patient's refusal to participate * any contraindications to peripheral nerve blocks * history of ischemic heart disease * patients on opioids for chronic pain * patients with significant cognitive impairment

Keywords: esp pain posterior cervical surgery
study of shr-a1921 in combination with other anti-cancer agents in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this research study is a multicentre phase ⅰb/ⅱ study to evaluate the efficacy and safety of shr-a1921 in combination with other anti-cancer agents in patients with advanced solid tumors


Eligibility criteria:
inclusion criteria: 1. male or female, 18-75 years; 2. be able to provide fresh or archived tumour tissue. 3. ph 1b: clinically or pathologically diagnosed advanced solid tumour . ph ii: histologically or cytologically confirmed, advanced or metastatic non-small cell lung cancer 4. with at least one measurable lesion (in accordance with recist v1.1) 5. eastern cooperative oncology group (ecog) score: 0-1. 6. with a life expectancy ≥ 12 weeks. 7. sufficient organ functions. 8. women of childbearing potential (wocbp) and male subjects whose partner are women of childbearing potential must agree to use a reliable and valid contraceptive method. exclusion criteria: 1. untreated brain metastasis or accompanied by meningeal metastases, spinal cord compression. 2. uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms. 3. previous or co-existing malignancies other than cured basal cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of the breast (dcis), papillary thyroid carcinoma, and other malignancies that have been adequately treated and cured for ≥3 years 4. hypertension that can not be well controlled through antihypertensive drugs (systolic blood pressure ≥ 140 mmhg or diastolic blood pressure ≥ 90 mmhg); previous hypertensive crisis or hypertensive encephalopathy. 5. with any active or known autoimmune disease 6. with active pulmonary tuberculosis infection
pio laser sclerectomy iop slt sclerectomy

Conditions: Primary Open-Angle Glaucoma

Summary: the main objective of this study is to characterize the changes in iop over 24 hours after selective trabeculoplasty slt (before and 1 and 6 months after treatment, decreased iop, type of rhythm, mesor, acrophase, amplitude). the secondary objective is to evaluate changes in ocular perfusion pressure (arterial pressure - iop) and ocular blood flow in the optic nerve head after selective laser trabeculoplasty.


Eligibility criteria:
inclusion criteria: * primary open-angle glaucoma * iop more than 21 mmhg * progression under maximal medical therapy * aged more than 18 years exclusion criteria: * pregnant woman
pharmacokinetic properties of lorcaserin in subjects with hepatic impairment

Conditions: Hepatic Impairment

Summary: the purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.


Eligibility criteria:
inclusion criteria: 1. males or females aged between 18 and 75 years (inclusive) 2. able to give signed informed consent 3. hepatic function will fall into one of the following categories: * one-third of patients will have normal hepatic function (defined as having all of the following parameters within the normal range of the clinical laboratory used for this trial: ast, alt, alkaline phosphatase, total bilirubin) * one-third of patients will have mild impairment (child-pugh score 5-6) * one-third of patients will have moderate impairment (child-pugh score 7-9) 4. all subjects will have a bmi of 27-45 kg/m2, inclusive. 5. eligible male and female patients must agree not to participate in a conception process 6. considered to be in stable health in the opinion of the investigator. exclusion criteria: 1. prior participation in any study of lorcaserin. 2. clinically significant new illness in the 1 month before screening 3. not suitable to participate in the study in the opinion of the investigator including an existing physical or mental condition that prevents compliance with the protocol 4. history of any of the following cardiovascular conditions: * myocardial infarction (diagnosed by cardiac enzyme\[s\] and/or diagnostic ecg), cva, tia or rind within 6 months of screening * cardiac arrhythmia requiring initiation of new medical or surgical treatment within 6 months of screening (stable medical therapy for \> 6 months, pacemakers and/or defibrillators implanted \> 6 months prior to screening are acceptable) * unstable angina 5. surgically implanted portacaval shunts are excluded with the following exception: transjugular intrahepatic portosystemic shunts (tips) will be allowed if placed no less than 3 months prior to dosing 6. malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins) 7. initiation of a new prescription medication within 1 month prior to screening. 8. recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening. 9. use of ssri's, snri's, and other medications must meet the required washout periods. 10. participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
the use of capsaicin challenge for diagnosis, monitoring and follow-up of chronic cough.

Conditions: Chronic Cough

Summary: the purpose of this study is to determine whether the capsaicin challenge can improve the diagnosis, treatment, monitoring and follow-up in patients with chronic cough.

capsaicin is administrated in incremental concentrations with two inhalations of normal saline solution. patients are instructed to exhale to functional residual capacity and than to inhale through the mouthpiece for 1 second (single breath inhalation). the number of coughs in the first 10 seconds after each inhalation is counted. c2; the concentration of which the patient responded by 2 coughs, c5;the concentration of which the patient responded by 5 coughs. the challenge ends at c5.

Eligibility criteria:
inclusion criteria: * patients with persisting cough for more than 3 months, without known respiratory or lung diseases exclusion criteria: * diagnosis of respiratory or lung diseases of any kind

Keywords: chronic cough cough reflex hypersensitivity capsaicin
effectiveness of trapeziometacarpal splint

Conditions: Osteoarthritis of Trapeziometacarpal Joint

Summary: the trapeziometacarpal osteoarthritis is a degenerative or inflammatory joint that affects the trapeziometacarpal joint (tmc) of the thumb. its main symptom is pain that leads to difficulty in manual function and decrease the patient's quality of life. immobilization of tmc thumb joint by bracing has been effective in reducing pain and improving function. objective: to compare the effectiveness between day and night functional splint for patients with trapeziometacarpal osteoarthritis in improving pain and function

randomized clinical trial, and blind where selected 60 patients diagnosed with trapeziometacarpal osteoarthritis.os patients were assessed by a blinded evaluator at the beginning of treatment and after 45, 90 and 180 days in relation to pain, thumb range of motion, strength hold, tweezers, dexterity, function and satisfaction.

Eligibility criteria:
inclusion criteria: * patients with osteoarthritis in accordance with the american college of rheumatology classification criteria (acr); of both genders and age above 18 years; pain in tmc articulation between 3 and 8 cm in numerical pain scale (end) 10cm exclusion criteria: * patients with severe deformities in hand with trapeziometacarpal osteoarthritis not possible to achieve pincer movement between the first, second and third fingers * deformity of the distal interphalangeal joint (ifd) of the thumb * use of splint the thumb in the last six months; have surgery scheduled on hand for the next six months * allergy to the material of the splint * inability to respond to the questionnaire and perform the tests * geographic inaccessibility * infiltration in hand in the previous 3 months * changes in the use of anti-inflammatory and analgesic past 3 months * physiotherapy in hand over the last 3 months * have the following related diseases: carpal tunnel syndrome, carpal fractures of dequervain syndrome, tendonitis, fibromyalgia and chronic inflammatory arthropathy.
naloxone methadone combination (nameko)

Conditions: Opiate Dependence

Summary: the aim of the study is to examine the tolerability and abuse potential of the diluted methadone solution (5 mg/ml → 2 mg/ml) in combination with naloxone in opioid substitution treatment. study hypothesis: treatment with this diluted combination product is safer than with methadone alone (5 mg/ml) and combination product does not precipitate withdrawal symptoms in opioid dependent patients.


Eligibility criteria:
inclusion criteria: * opioid dependence * methadone treatment * no changes in methadone dose during the last 10 days * good treatment compliance according to doctor * normal alat and afos values (increased if double the normal level) exclusion criteria: * severe renal or hepatic failure * acute psychosis * age under 18 * pregnancy * legal incompetence * severe somatic disease * chaotic situation in life * medication or disease which is contraindication to study treatment

Keywords: opiate dependence methadone naloxone withdrawal symptom substitution treatment